Posted by Michael Wonder on 08 Mar 2025
Acarizax approved in Canada for treatment of young children
7 March 2025 - ALK today announced that Health Canada has approved ALK’s Acarizax tablet for use in children, aged five to 11, with house dust mite allergy.
Acarizax is now indicated for treatment of moderate to severe house dust mite allergen induced allergic rhinitis, with or without conjunctivitis, in children, adolescents, and adults in Canada aged five to 65.
